A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Paroxetine
  • Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Generalised anxiety disorder; Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 22 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top